- Home
- KPTI vs VIVK Comparison
KPTI vs VIVK Comparison
Compare KPTI & VIVK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- VIVK
- Stock Information
- Founded
- KPTI 2008
- VIVK 2006
- Country
- KPTI United States
- VIVK United States
- Employees
- KPTI N/A
- VIVK N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- VIVK Oilfield Services/Equipment
- Sector
- KPTI Health Care
- VIVK Energy
- Exchange
- KPTI Nasdaq
- VIVK Nasdaq
- Market Cap
- KPTI 44.5M
- VIVK 38.4M
- IPO Year
- KPTI 2013
- VIVK N/A
- Fundamental
- Price
- KPTI $5.92
- VIVK $0.83
- Analyst Decision
- KPTI Buy
- VIVK
- Analyst Count
- KPTI 6
- VIVK 0
- Target Price
- KPTI $39.80
- VIVK N/A
- AVG Volume (30 Days)
- KPTI 221.8K
- VIVK 348.9K
- Earning Date
- KPTI 08-11-2025
- VIVK 08-26-2025
- Dividend Yield
- KPTI N/A
- VIVK N/A
- EPS Growth
- KPTI N/A
- VIVK N/A
- EPS
- KPTI N/A
- VIVK N/A
- Revenue
- KPTI $137,269,000.00
- VIVK $111,130,140.00
- Revenue This Year
- KPTI $2.18
- VIVK N/A
- Revenue Next Year
- KPTI $11.28
- VIVK N/A
- P/E Ratio
- KPTI N/A
- VIVK N/A
- Revenue Growth
- KPTI N/A
- VIVK 85.84
- 52 Week Low
- KPTI $3.51
- VIVK $0.55
- 52 Week High
- KPTI $16.95
- VIVK $2.05
- Technical
- Relative Strength Index (RSI)
- KPTI 72.07
- VIVK 43.37
- Support Level
- KPTI $3.65
- VIVK $0.81
- Resistance Level
- KPTI $4.35
- VIVK $1.07
- Average True Range (ATR)
- KPTI 0.50
- VIVK 0.14
- MACD
- KPTI 0.17
- VIVK -0.02
- Stochastic Oscillator
- KPTI 70.06
- VIVK 3.82
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About VIVK Vivakor Inc.
Vivakor Inc is a socially responsible operator, acquirer and developer of technologies and assets in the oil and gas industry, as well as related environmental solutions. It is focused on operating crude oil gathering, storage and transportation facilities, as well as contaminated soil remediation services. Company have two operating business segments: Transportation logistics services; Terminaling and storage facility product and services related to oil and gas production. Majority of revenue is from Terminaling and storage segment.